Tags

Type your tag names separated by a space and hit enter

Impact of ivermectin on illness and disability associated with onchocerciasis.
Trop Med Int Health. 2004 Apr; 9(4):A45-56.TM

Abstract

The Onchocerciasis Control Program (OCP), one of the most successful vertical disease control programs in the history of public health, came to an end in 2003 with devolvement of responsibilities for control program activities passed to the countries affected. Fortunately, 15 years ago the Mectizan Distribution Program (MDP) was founded to provide a complementary approach to controlling the disabling consequences of this parasitic infection. With over 250 million doses of ivermectin distributed over the past 15 years, the MDP is well on its way to both solidifying the progress made by the OCP and extending program reach well beyond the boundaries of the OCP. Through the extensive clinical testing protocols implemented in a variety of countries in Aftica, ivermectin has been proven to be a safe and highly effective treatment for onchocerciasis. Regular distribution to populations living in endemic areas has demonstrated significant reductions in blinding ocular complications, transmission, and disability caused by onchocercal skin disease. As yet undocumented, are the likely significant impact regular population dosing with ivermectin has on intestinal helminth infections, lymphatic filariasis, and human scabies infection. While there are significant barriers to continued program success, focussed attention on expanding and improving community-directed ivermectin distribution is likely to lead to further progress against this resilient infection.

Authors+Show Affiliations

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. jtielsch@jhsph.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15078278

Citation

Tielsch, James M., and Arlyne Beeche. "Impact of Ivermectin On Illness and Disability Associated With Onchocerciasis." Tropical Medicine & International Health : TM & IH, vol. 9, no. 4, 2004, pp. A45-56.
Tielsch JM, Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Health. 2004;9(4):A45-56.
Tielsch, J. M., & Beeche, A. (2004). Impact of ivermectin on illness and disability associated with onchocerciasis. Tropical Medicine & International Health : TM & IH, 9(4), A45-56.
Tielsch JM, Beeche A. Impact of Ivermectin On Illness and Disability Associated With Onchocerciasis. Trop Med Int Health. 2004;9(4):A45-56. PubMed PMID: 15078278.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of ivermectin on illness and disability associated with onchocerciasis. AU - Tielsch,James M, AU - Beeche,Arlyne, PY - 2004/4/14/pubmed PY - 2004/7/9/medline PY - 2004/4/14/entrez SP - A45 EP - 56 JF - Tropical medicine & international health : TM & IH JO - Trop. Med. Int. Health VL - 9 IS - 4 N2 - The Onchocerciasis Control Program (OCP), one of the most successful vertical disease control programs in the history of public health, came to an end in 2003 with devolvement of responsibilities for control program activities passed to the countries affected. Fortunately, 15 years ago the Mectizan Distribution Program (MDP) was founded to provide a complementary approach to controlling the disabling consequences of this parasitic infection. With over 250 million doses of ivermectin distributed over the past 15 years, the MDP is well on its way to both solidifying the progress made by the OCP and extending program reach well beyond the boundaries of the OCP. Through the extensive clinical testing protocols implemented in a variety of countries in Aftica, ivermectin has been proven to be a safe and highly effective treatment for onchocerciasis. Regular distribution to populations living in endemic areas has demonstrated significant reductions in blinding ocular complications, transmission, and disability caused by onchocercal skin disease. As yet undocumented, are the likely significant impact regular population dosing with ivermectin has on intestinal helminth infections, lymphatic filariasis, and human scabies infection. While there are significant barriers to continued program success, focussed attention on expanding and improving community-directed ivermectin distribution is likely to lead to further progress against this resilient infection. SN - 1360-2276 UR - https://www.unboundmedicine.com/medline/citation/15078278/full_citation L2 - https://doi.org/10.1111/j.1365-3156.2004.01213.x DB - PRIME DP - Unbound Medicine ER -